Patents by Inventor Michael Lamsa

Michael Lamsa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190316103
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: May 23, 2019
    Publication date: October 17, 2019
    Applicants: NOVOZYMES, INC., Novozymes A/S
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Bjarne Gram Hansen, Frank Winther Rasmussen, Matt Sweeney, Douglas J. Boyle III
  • Patent number: 10351834
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: July 16, 2019
    Assignees: Novozymes, Inc., Novozymes A/S
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Bjarne Gram Hansen, Frank Winther Rasmussen, Matt Sweeney, Douglas J. Boyle, III
  • Publication number: 20190153414
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: February 6, 2019
    Publication date: May 23, 2019
    Applicants: Novozymes, Inc.
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Matt Sweeney, Mark Wogulis, Elizabeth Znameroski, Frank Winther Rasmussen
  • Patent number: 10227579
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: March 12, 2019
    Assignees: Novozymes A/S, Novozymes, Inc.
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Matt Sweeney, Mark Wogulis, Elizabeth Znameroski, Frank Winther Rasmussen
  • Patent number: 9539311
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: January 10, 2017
    Assignees: Novozymes A/S, Novozymes Inc.
    Inventors: Allan Svendsen, Michael Skjoet, Debbie Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Publication number: 20160168547
    Abstract: The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 16, 2016
    Applicants: Novozymes Inc., Novozymes A/S
    Inventors: Suzanne Otani, Debbie Yaver, Haiyan Ge, Janine Lin, Christopher Amolo, Kim Borch, Shamkant Anant Patkar, Michael Lamsa, Barbara Cherry
  • Patent number: 9303248
    Abstract: The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: April 5, 2016
    Assignees: NOVOZYMES A/S, NOVOZYMES, INC.
    Inventors: Suzanne Otani, Debbie Yaver, Haiyan Ge, Janine Lin, Christopher Amolo, Kim Borch, Shamkant Anant Patkar, Michael Lamsa, Barbara Cherry
  • Publication number: 20150209414
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Application
    Filed: April 6, 2015
    Publication date: July 30, 2015
    Inventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Patent number: 9080165
    Abstract: The present invention relates to variants of a parent beta-glucosidase, comprising a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant has beta-glucosidase activity. The present invention also relates to nucleotide sequences encoding the variant beta-glucosidases and to nucleic acid constructs, vectors, and host cells comprising the nucleotide sequences.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: July 14, 2015
    Assignee: Novozymes, Inc.
    Inventors: Ana Fidantsef, Michael Lamsa, Brian Gorre-Clancy
  • Patent number: 9045748
    Abstract: The present invention relates to methods for expression screening of filamentous fungal transformants, comprising: (a) isolating single colony transformants of a DNA library introduced into E. coli; (b) preparing DNA from each of the single colony E. coli transformants; (c) introducing a sample of each of the DNA preparations of step (b) into separate suspensions of protoplasts of a filamentous fungus to obtain transformants thereof, wherein each transformant contains one or more copies of an individual polynucleotide from the DNA library; (d) growing the individual filamentous fungal transformants of step (c) on selective growth medium, thereby permitting growth of the filamentous fungal transformants, while suppressing growth of untransformed filamentous fungi; and (e) measuring activity or a property of each polypeptide encoded by the individual polynucleotides.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: June 2, 2015
    Assignee: Novozymes, Inc.
    Inventors: Sarah Teter, Michael Lamsa, Joel Cherry, Connie Ward
  • Patent number: 9029115
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: May 12, 2015
    Assignees: Novozymes A/S, Novozymes Inc
    Inventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Publication number: 20150099280
    Abstract: The present invention relates to variants of a parent beta-glucosidase, comprising a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant has beta-glucosidase activity. The present invention also relates to nucleotide sequences encoding the variant beta-glucosidases and to nucleic acid constructs, vectors, and host cells comprising the nucleotide sequences.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Inventors: Ana Fidantsef, Michael Lamsa, Brian Gorre-Clancy
  • Publication number: 20150082493
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 19, 2015
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Matt Sweeney, Mark Wogulis, Elizabeth Znameroski, Frank Winther Rasmussen
  • Publication number: 20150007369
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: November 21, 2012
    Publication date: January 1, 2015
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Bjarne Gram Hansen, Frank Winther Rasmussen, Matt Sweeney, Douglas J. Boyle, III
  • Patent number: 8852913
    Abstract: The present invention relates to variants of a parent beta-glucosidase, comprising a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant has beta-glucosidase activity. The present invention also relates to nucleotide sequences encoding the variant beta-glucosidases and to nucleic acid constructs, vectors, and host cells comprising the nucleotide sequences.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: October 7, 2014
    Assignee: Novozymes, Inc.
    Inventors: Ana Fidantsef, Michael Lamsa, Brian Gorre-Clancy
  • Patent number: 8563286
    Abstract: The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 22, 2013
    Assignees: Novozymes, Inc., Novozymes A/S
    Inventors: Debbie Yaver, Janine Lin, Michael Lamsa, Kim Borch, Shamkant Anant Patkar
  • Patent number: 8377675
    Abstract: The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: February 19, 2013
    Assignee: Novozymes, Inc.
    Inventors: Suzanne Otani, Debbie Yaver, Haiyan Ge, Janine Lin, Christopher Amolo, Kim Borch, Shamkant Anant Patkar, Michael Lamsa, Barbara Cherry
  • Publication number: 20130025005
    Abstract: The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Application
    Filed: August 30, 2012
    Publication date: January 24, 2013
    Applicants: Novozymes A/S, Novozymes, Inc.
    Inventors: Debbie Yaver, Suzanne Otani, Janine Lin, Christopher Amolo, Kim Borch, Shamkant Anant Patkar, Michael Lamsa, Barbara Cherry
  • Publication number: 20120308543
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 6, 2012
    Applicants: NOVOZYMES, INC., NOVOZYMES A/S
    Inventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Patent number: 8273348
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: September 25, 2012
    Assignees: Novozymes A/S, Novozymes Inc.
    Inventors: Allan Svendsen, Michael Skjoet, Debbie Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory